Orexigen Therapeutics Inc., of San Diego, said it closed its offering of $115 million aggregate principal amount of convertible senior notes due 2020, including $15 million aggregate principal amount of the notes issued in connection with the exercise by initial purchases of their option to purchase additional notes.